全文获取类型
收费全文 | 2488篇 |
免费 | 116篇 |
国内免费 | 49篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 137篇 |
妇产科学 | 45篇 |
基础医学 | 338篇 |
口腔科学 | 34篇 |
临床医学 | 262篇 |
内科学 | 557篇 |
皮肤病学 | 30篇 |
神经病学 | 217篇 |
特种医学 | 218篇 |
外科学 | 187篇 |
综合类 | 22篇 |
一般理论 | 1篇 |
预防医学 | 109篇 |
眼科学 | 9篇 |
药学 | 203篇 |
中国医学 | 9篇 |
肿瘤学 | 262篇 |
出版年
2023年 | 10篇 |
2022年 | 27篇 |
2021年 | 34篇 |
2020年 | 20篇 |
2019年 | 29篇 |
2018年 | 51篇 |
2017年 | 36篇 |
2016年 | 39篇 |
2015年 | 42篇 |
2014年 | 71篇 |
2013年 | 86篇 |
2012年 | 120篇 |
2011年 | 141篇 |
2010年 | 107篇 |
2009年 | 104篇 |
2008年 | 164篇 |
2007年 | 156篇 |
2006年 | 160篇 |
2005年 | 125篇 |
2004年 | 144篇 |
2003年 | 136篇 |
2002年 | 112篇 |
2001年 | 22篇 |
2000年 | 26篇 |
1999年 | 25篇 |
1998年 | 73篇 |
1997年 | 67篇 |
1996年 | 58篇 |
1995年 | 45篇 |
1994年 | 41篇 |
1993年 | 42篇 |
1992年 | 14篇 |
1991年 | 20篇 |
1990年 | 13篇 |
1989年 | 40篇 |
1988年 | 25篇 |
1987年 | 26篇 |
1986年 | 19篇 |
1985年 | 20篇 |
1984年 | 24篇 |
1983年 | 20篇 |
1982年 | 16篇 |
1981年 | 22篇 |
1980年 | 22篇 |
1979年 | 5篇 |
1978年 | 12篇 |
1977年 | 11篇 |
1976年 | 12篇 |
1975年 | 7篇 |
1973年 | 3篇 |
排序方式: 共有2653条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
Normal and diseased isolated lungs: high-resolution CT 总被引:8,自引:0,他引:8
6.
Lutz Fritsche Gunilla Einecke Franca Fleiner Duska Dragun Hans-Hellmut Neumayer Klemens Budde 《American journal of transplantation》2004,4(5):738-743
The reporting quality of publications of clinical trials can affect the quality of clinical decision-making. We systematically assessed the quality of publications of large multicenter trials evaluating immunosuppressive regimens in de novo kidney transplantation. Study quality, reporting quality and accessibility of the results of 63 publications were assessed independently by three blinded investigators using an instrument combining the Jadad scale with a list of reporting quality items. Study quality was rated with an average of only 2.3 (range 1-5) on the Jadad scale. Unblinded studies were reported in 68.3% of publications and follow-up longer than 12 months was reported for only 13 out of 50 studies. The reviewed publications fulfilled an average of 69.1% of the reporting quality criteria. Fifty-four percent of publications did not report both treated and biopsy-proven rejections. Whether reported graft survival was censored for death could not be determined for 27% of publications. Only a few publications gave confidence intervals (CIs) or stated whether additional analyses were pre-specified. Even the largest trials of immunosuppression in kidney transplantation show considerable quality deficits in their design and publication. Additional efforts are required of investigators, editors and sponsors to achieve maximum study and reporting quality. 相似文献
7.
8.
The adhesion of hematopoietic progenitor cells to bone marrow stromal cells is critical to hematopoiesis and involves multiple effector molecules. Stromal cell molecules that participate in this interaction were sought by analyzing the detergent-soluble membrane proteins of GBI/6 stromal cells that could be adsorbed by intact FDCP-1 progenitor cells. A single-chain protein from GBI/6 cells having an apparent molecular weight of 37 Kd was selectively adsorbed by FDCP-1 cells. This protein, designated p37, could be surface-radiolabeled and thus appeared to be exposed on the cell membrane. An apparently identical 37- Kd protein was expressed by three stromal cell lines, by Swiss 3T3 fibroblastic cells, and by FDCP-1 and FDCP-2 progenitor cells. p37 was selectively adsorbed from membrane lysates by a variety of murine hematopoietic cells, including erythrocytes, but not by human erythrocytes. Binding of p37 to cells was calcium-dependent, and was not affected by inhibitors of the hematopoietic homing receptor or the cell-binding or heparin-binding functions of fibronectin. It is proposed that p37 may be a novel adhesive molecule expressed on the surface of a variety of hematopoietic cells that could participate in both homotypic and heterotypic interactions of stromal and progenitor cells. 相似文献
9.
10.
Franca Formelli Loredana Cleris Roberto Carsana 《Cancer chemotherapy and pharmacology》1988,21(4):329-336
Summary The effect of the combined administration of verapamil (i.p. twice daily) and doxorubicin (i.v once weekly) was tested in mice bearing the following: (a) a tumor with induced resistance to doxorubicin (B16VDXR melanoma line); (b) a tumor inherently resistant (MXT mammary carcinoma); and (c) four solid tumors sensitive to doxorubicin (B16 melanoma, B16V melanoma line, M5076 reticulum cell sarcoma, and Lewis lung carcinoma). Verapamil, given according to this treatment schedule, reached peak plasma concentrations of 3 M. Such treatment did not enhance doxorubicin activity on either inherently or induced resistant tumors, whereas it significantly enhanced doxorubicin growth inhibition in all the sensitive tumors except the Lewis lung carcinoma. Doxorubicin pharmacokinetics after administration of the drug alone and in combination with verapamil was analyzed after the first and repeated treatments in animals bearing B16 melanoma or its resistant subline B16VDXR. The resistance of the B16VDXR line was associated with the ability of the tumor to retain less doxorubicin (AUC=83 g h/g) than the sensitive tumor B16 (AUC=204 g h/g) in spite of similar initial levels. The potentiating effect of doxorubicin activity by, verapamil in B16 melanoma was not associated with increased doxorubicin levels or retention in the tumor, nor were differences in doxorubicin levels or retention found in the B16VDXR line. The combined treatment did not modify doxorubicin pharmacokinetics in plasma, heart, or spleen. These studies suggest that verapamil in vivo is ineffective in potentiating doxorubicin activity in tumors against which doxorubicin is inactive, that sensitive tumors are heterogeneous in their sensitivity to modulation by verapamil, and that this effect is not associated with modification of doxorubicin pharmacokinetics.This work was supported by grant no. 84.00855.44 of the Finalized Project Oncologia from the Consiglio Nazionale delle Ricerche, Rome 相似文献